Author:
Dodel Richard,Kruse Christopher,Conrads-Frank Annette,Siebert Uwe
Publisher
Springer International Publishing
Reference204 articles.
1. Ademi Z, Pasupathi K, Liew D. Cost-effectiveness of apixaban compared to warfarin in the management of atrial fibrillation in Australia. Eur J Prev Cardiol. 2015;22:344–53.
2. Adi Y, Juarez-Garcia A, Wang D, et al. Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation. Health Technol Assess. 2007;11: iii-iv, 1–85.
3. Amiri A, Goudarzi R, Amiresmaili M, et al. Cost-effectiveness analysis of tissue plasminogen activator in acute ischemic stroke in Iran. J Med Econ. 2018;21:282–7.
4. Ankjaer-Jensen A, Sejr TE. Costs of the treatment of enuresis nocturna. Health economic consequences of alternative methods in the treatment of enuresis nocturna. Ugeskr Laeger. 1994;156:4355–60.
5. Aspinall SL, Smith KJ, Cunningham FE, et al. Incremental cost-effectiveness of various monthly doses of vardenafil. Value Health. 2011;14:97–101.